Introduction & Objective: In the midst of the COVID-19 pandemic in 2020 and 2021, we reported a significant increase in homeostatic model assessment for insulin resistance (HOMA-IR) values among 14-15 years old students. In this study, we conducted prolonged surveys incorporating data until 2023.
Methods: The study included 430 students aged 14-15 who underwent health examinations between 2015 and 2023 (236 males, 194 females). Using its data, HOMA-IR, BMI, and obesity levels were calculated, and temporal changes were assessed using the Kruskal-Wallis test. Insulin resistance (IR) is defined as HOMA-IR ≥2.5 and temporal changes were assessed using the Chi-square test.
Results: A significant change in the median HOMA-IR was observed over the 8-year period (p < 0.001). Conversely, no significant differences were observed in the median BMI and obesity levels over the 8-year period (p = 0.055, p = 0.064). Figure1 illustrated changes in the proportion of study participants with IR over time.
Conclusion: The significant increase in HOMA-IR observed after 2020 significantly decreased to values similar to pre-COVID-19 levels by 2023. However, BMI and obesity levels showed no temporal changes. Our findings suggest that changes in lifestyle due to the COVID-19 pandemic may have influenced insulin resistance in 14-15 years old students, irrespective of obesity status during 2020-2022.
T. Ohno: None. M. Ishiguro: None. Y. Suganuma: None. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation.
Ministry of Education, Culture, Sports, Science, and Technology, Japan (Kiban [c] 23590815 and Kiban [c] 19590600)
